These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34180282)

  • 21. Contribution of cabotegravir + rilpivirine long-acting for the treatment of HIV-1 infection.
    Calleja-Hernández MÁ; Martinez-Sesmero JM; Vallejo-Aparicio LA; Hernández-Novoa B; Badia X
    Farm Hosp; 2022 Jul; 46(4):208-214. PubMed ID: 36183218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-acting cabotegravir/rilpivirine for HIV-1 treatment: real-world evaluation of barriers to implementation.
    Wood BR; Kassaye SG; Gerstoft J
    AIDS; 2023 Mar; 37(4):689-691. PubMed ID: 36815522
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.
    Palacios R; Pérez-Hernández IA; Martínez MA; Mayorga ML; González-Domenech CM; Omar M; Olalla J; Romero A; Romero JM; Pérez-Camacho I; Hernández-Quero J; Santos J
    Eur J Clin Microbiol Infect Dis; 2016 May; 35(5):815-9. PubMed ID: 26879392
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
    Letendre SL; Mills A; Hagins D; Swindells S; Felizarta F; Devente J; Bettacchi C; Lou Y; Ford S; Sutton K; Shaik JS; Crauwels H; D'Amico R; Patel P
    J Antimicrob Chemother; 2020 Mar; 75(3):648-655. PubMed ID: 31873746
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Efficacy of Dolutegravir Plus Rilpivirine in Treatment-Experienced HIV-Infected Patients: The DORIVIR Study.
    Palacios R; Mayorga M; González-Domenech CM; Hidalgo-Tenorio C; Gálvez C; Muñoz-Medina L; de la Torre J; Lozano A; Castaño M; Omar M; Santos J
    J Int Assoc Provid AIDS Care; 2018; 17():2325958218760847. PubMed ID: 29529910
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries.
    Steegen K; Chandiwana N; Sokhela S; Venter WDF; Hans L
    AIDS; 2023 May; 37(6):1009-1011. PubMed ID: 36779485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brief Report: Durable Suppression and Low Rate of Virologic Failure 3 Years After Switch to Dolutegravir + Rilpivirine 2-Drug Regimen: 148-Week Results From the SWORD-1 and SWORD-2 Randomized Clinical Trials.
    van Wyk J; Orkin C; Rubio R; Bogner J; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Matthews J; Wang R; Underwood M; Wynne B; Nascimento MC; Vandermeulen K; Gartland M; Smith KY
    J Acquir Immune Defic Syndr; 2020 Nov; 85(3):325-330. PubMed ID: 32675772
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Pharmacological properties of rilpivirine (Edurant Tablet), a new drug for the treatment of HIV, and results of its clinical studies].
    Iwata M; Shikinami K; Nagino K; Harada Y
    Nihon Yakurigaku Zasshi; 2013 Apr; 141(4):205-11. PubMed ID: 23575426
    [No Abstract]   [Full Text] [Related]  

  • 30. Prevalence of genotypic baseline risk factors for cabotegravir + rilpivirine failure among ARV-naive patients.
    Charpentier C; Storto A; Soulié C; Ferré VM; Wirden M; Joly V; Lambert-Niclot S; Palich R; Morand-Joubert L; Landman R; Lacombe K; Katlama C; Ghosn J; Marcelin AG; Calvez V; Descamps D
    J Antimicrob Chemother; 2021 Oct; 76(11):2983-2987. PubMed ID: 34015097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice.
    Borghetti A; Farinacci D; Ciccullo A; Dusina A; Moschese D; Iannone V; D'Angelillo A; Lombardi F; Donne VD; Massaroni V; Visconti E; Tamburrini E; Di Giambenedetto S
    J Med Virol; 2022 Oct; 94(10):4970-4974. PubMed ID: 35638227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
    Swindells S; Andrade-Villanueva JF; Richmond GJ; Rizzardini G; Baumgarten A; Masiá M; Latiff G; Pokrovsky V; Bredeek F; Smith G; Cahn P; Kim YS; Ford SL; Talarico CL; Patel P; Chounta V; Crauwels H; Parys W; Vanveggel S; Mrus J; Huang J; Harrington CM; Hudson KJ; Margolis DA; Smith KY; Williams PE; Spreen WR
    N Engl J Med; 2020 Mar; 382(12):1112-1123. PubMed ID: 32130809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sex and Gender Differences in Rilpivirine based ART - Data from the HIVCENTER Frankfurt.
    Schüttfort G; Philipp K; de Leuw P; Herrmann E; Kann G; Khaykin P; Stephan C; Wolf T; Haberl A
    Curr HIV Res; 2019; 17(5):368-374. PubMed ID: 31686639
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks.
    Murray M; Antela A; Mills A; Huang J; Jäger H; Bernal E; Lombaard J; Katner H; Walmsley S; Khuong-Josses MA; Hudson K; Dorey D; Griffith S; Spreen W; Vanveggel S; Shaefer M; Margolis D; Chounta V
    AIDS Behav; 2020 Dec; 24(12):3533-3544. PubMed ID: 32447500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial.
    Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S
    Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cabotegravir and Rilpivirine.
    Am J Health Syst Pharm; 2021 May; 78(11):925-931. PubMed ID: 33822851
    [No Abstract]   [Full Text] [Related]  

  • 37. Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modeling Study.
    Bettonte S; Berton M; Stader F; Battegay M; Marzolini C
    Clin Infect Dis; 2023 Apr; 76(7):1225-1236. PubMed ID: 36377436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rilpivirine (Edurant)--a new drug for HIV infection.
    Med Lett Drugs Ther; 2011 Aug; 53(1371):67-8. PubMed ID: 21860365
    [No Abstract]   [Full Text] [Related]  

  • 39. Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: A modelling study.
    Parker B; Ward T; Hayward O; Jacob I; Arthurs E; Becker D; Anderson SJ; Chounta V; Van de Velde N
    PLoS One; 2021; 16(2):e0245955. PubMed ID: 33529201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Promise of Improved Adherence With Long-Acting Antiretroviral Therapy: What Are the Data?
    Scarsi KK; Swindells S
    J Int Assoc Provid AIDS Care; 2021; 20():23259582211009011. PubMed ID: 33902356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.